登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
A Phase II Study of QL1706 With Anti-angiogenesis Therapy and Chemotherapy in Extensive-stage Small Cell Lung Cancer.
ClinicalTrials.gov 上登记的一项肺癌开放试验,由中国医学科学院肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07083375,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 7
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(7 项)收起清单
18 岁 至 未注明;性别:不限
登记记录的入选字段
Histologically or cytologically confirmed, treatment-naïve extensive-stage small cell lung cancer (ES-SCLC).
入选标准第 5 条
ECOG performance status of 0 or 1.
入选标准第 4 条
Absolute neutrophil count ≥1.5 × 10⁹/L
入选标准第 10 条
Platelets ≥100 × 10⁹/L
入选标准第 11 条
Hemoglobin ≥90 g/L (without transfusion in prior 14 days)
入选标准第 12 条
Serum creatinine ≤1× ULN or creatinine clearance >50 mL/min (Cockcroft-Gault)
入选标准第 13 条
AST and ALT ≤2.5× ULN (≤5× ULN with liver metastases)
入选标准第 14 条
Total bilirubin ≤1.5× ULN (except Gilbert's syndrome <51.3 µmol/L)
入选标准第 15 条
At least one measurable lesion per RECIST v1.1.
入选标准第 7 条
Positive for HIV antibodies, active HBV (HBsAg+ with HBV DNA >10³ copies/mL), or active HCV infection (HCV-Ab+ with detectable RNA).
排除标准第 9 条
History of other malignancies within 2 years, except for cured non-melanoma skin cancers or certain in situ carcinomas.
排除标准第 13 条
Pregnant or breastfeeding females.
排除标准第 7 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);既往治疗。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07083375,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Signed written informed consent and willingness to comply with study procedures. Age ≥18 years. Estimated life expectancy ≥3 months. ECOG performance status of 0 or 1. Histologically or cytologically confirmed, treatment-naïve extensive-stage small cell lung cancer (ES-SCLC). Willing to provide archived or fresh tumor tissue samples. If unavailable, enrollment may proceed per investigator assessment. At least one measurable lesion per RECIST v1.1. Fully understands and voluntarily participates in the study. Adequate organ function as defined below: Absolute neutrophil count ≥1.5 × 10⁹/L Platelets ≥100 × 10⁹/L Hemoglobin ≥90 g/L (without transfusion in prior 14 days) Serum creatinine ≤1× ULN or creatinine clearance >50 mL/min (Cockcroft-Gault) AST and ALT ≤2.5× ULN (≤5× ULN with liver metastases) Total bilirubin ≤1.5× ULN (except Gilbert's syndrome <51.3 µmol/L) TSH, FT3, FT4 within ±10% of normal limits排除标准:Exclusion Criteria:
Prior chemotherapy, immunotherapy, targeted therapy, or radiotherapy. Histologic or cytologic evidence of non-small cell or mixed small cell/non-small cell carcinoma. Symptomatic brain metastases or leptomeningeal disease. Active or suspected autoimmune disease, except for stable vitiligo, type 1 diabetes, hypothyroidism requiring only hormone replacement, or conditions not expected to recur. Evidence or history of active pulmonary tuberculosis (TB), including treated TB within the past year. Concomitant condition requiring systemic corticosteroids or other immunosuppressive therapy. Pregnant or breastfeeding females. Symptomatic interstitial lung disease or suspected drug-related pneumonitis. Positive for HIV antibodies, active HBV (HBsAg+ with HBV DNA >10³ copies/mL), or active HCV infection (HCV-Ab+ with detectable RNA). History of significant neurological or psychiatric disorders (e.g., dementia, depression, epilepsy, bipolar disorder). Participation in another investigational drug study within 4 weeks prior to randomization. Use of anti-tumor traditional Chinese medicine within 2 weeks prior to first study dose. History of other malignancies within 2 years, except for cured non-melanoma skin cancers or certain in situ carcinomas. Clinically significant cardiovascular or cerebrovascular disease (e.g., NYHA class ≥2 heart failure, recent myocardial infarction or stroke within 6 months). History of thromboembolic events (e.g., DVT, PE, arterial thrombosis) within 6 months, except catheter-related thrombosis. Live vaccination within 28 days before randomization or planned during the study. Major surgery or significant trauma within 4 weeks prior to treatment initiation. Conditions affecting drug absorption (e.g., severe vomiting, GI obstruction, active GI bleeding or perforation). Active, uncontrolled bacterial, viral, or fungal infections despite appropriate treatment. Known hypersensitivity to any study drug or excipients. Any other condition deemed unsuitable by the investigator due to safety or compliance concerns.
引自 ClinicalTrials.gov, NCT07083375, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07083375,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。